Reneo Pharmaceuticals
Reneo Pharmaceuticals is a pre-revenue, clinical-stage biopharmaceutical company founded in 2014 and based in San Diego that develops therapies for patients with orphan metabolic diseases. It is funded by dedicated life sciences investors and has no approved products or revenue.
- Company typePublic
- Founded2014
- HeadquartersSan Diego, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Reneo Pharmaceuticals does
Reneo Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in San Diego, California, focused on developing therapies for patients with orphan metabolic diseases. The company operates as a for-profit, publicly traded entity (previously NASDAQ: RPHM, now delisted) with a headcount of 51-100 employees and a leadership team spanning co-founder/CEO, COO, CFO, CMO, VP of Clinical Operations, and a Head of Patient Engagement and Communications. Its strategic positioning is in the rare disease drug development segment, where orphan drug designation pathways and small, identifiable patient populations are typical competitive dynamics.
Reneo's business model is that of a pre-revenue drug developer: capital is raised through equity financings (including a $95M Series B in December 2020 co-led by Abingworth and Novo Ventures, a $20M round in May 2022, and a $55M public offering with concurrent Abingworth private placement in May 2023) and deployed into research and clinical development of metabolic disease therapeutics. The company has no approved products, no disclosed revenue, and no disclosed pricing model. Its funding base — New Enterprise Associates, Abingworth Bioventures, Novo Ventures, Lundbeckfonden Ventures, Chiesi Ventures, Pappas Capital, RiverVest, Rock Springs Capital, Aisling Capital, and Amzak Health Investors — reflects a syndicate of dedicated life sciences investors.
Financial performance shows deepening operating losses year over year (from roughly -$15M in 2019 toward -$80M+ in 2023), characteristic of a clinical pipeline burning cash against accumulated funding. There is no evidence of commercial partnerships, licensing deals, or revenue-generating collaborations in the input. The combination of pre-revenue status, delisting, widening losses, and absence of disclosed product launches points to a company either in late-stage pipeline development awaiting a catalytic event or in a restructuring/transitional phase. No artificial intelligence or machine learning capabilities are referenced in the available data.
Reneo Pharmaceuticals firmographics
Firmographics- Name
- Reneo Pharmaceuticals
- Legal name
- Reneo Pharmaceuticals
- Website
- https://reneopharma.com
- Company type
- Public
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Reneo Pharmaceuticals is a pre-revenue, clinical-stage biopharmaceutical company founded in 2014 and based in San Diego that develops therapies for patients with orphan metabolic diseases. It is funded by dedicated life sciences investors and has no approved products or revenue.
- Ownership category
- akta.pro rank
Reneo Pharmaceuticals industry classification
Industry- Product category
- Rare Disease Pharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Enzyme Replacement & Metabolic Disorder Therapies (HLAIAIAB)
- akta.pro secondary industries
- Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)
Keywords
Where Reneo Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Markets served
Reneo Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations
Reneo Pharmaceuticals product offering
Product offeringCore offering
Reneo Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule therapies for orphan metabolic diseases, including rare genetic mitochondrial and metabolic disorders. The company is pre-revenue and focused on discovering, developing, and advancing its proprietary pipeline of drug candidates through clinical trials targeting conditions of high unmet medical need.
Differentiator
Problem solved
Functional benefit
Companies that use Reneo Pharmaceuticals
Customer profileIdeal customer profiles1 record
Reneo Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Reneo Pharmaceuticals partnerships and signals
Strategic signalScale indicators1 record
Recent moves5 records
Expansion highlights3 records
Reneo Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- BioMarin Pharmaceutical: BioMarin is a global leader in rare metabolic disease therapies (e.g., PKU, MPS), making it the most directly comparable commercial-stage orphan metabolic disease peer for Reneo's pipeline focus.
- Travere Therapeutics: Travere develops therapies for rare kidney and metabolic diseases, sharing Reneo's orphan-disease, small-cap clinical-to-commercial profile and similar regulatory pathway dynamics.
- Ultragenyx Pharmaceutical: Ultragenyx develops and commercializes therapies for rare and ultra-rare metabolic diseases, with overlapping indication strategy and similar orphan-drug commercial dynamics as Reneo.
- Amicus Therapeutics: Amicus focuses on rare metabolic diseases including Fabry disease and Pompe disease, with a clinical-stage to commercial orphan-disease pipeline directly comparable to Reneo's model.
- BridgeBio Pharma: BridgeBio targets genetic and rare diseases with a multi-asset R&D model, providing a relevant peer for Reneo's small-molecule approach to inherited metabolic disorders.
Broad incumbents
- Horizon Therapeutics (Amgen): Horizon Therapeutics, acquired by Amgen, operates a broad rare-disease portfolio with metabolic and endocrine therapies, reflecting the large-pharma orphan-disease M&A pathway available to Reneo as an exit.
- Alexion (AstraZeneca Rare Disease): Alexion, now part of AstraZeneca, is a broad rare-disease franchise with multiple commercial metabolic and enzyme-replacement therapies, representing the strategic-acquisition benchmark for orphan metabolic companies like Reneo.
Emerging players
- Aeglea BioTherapeutics: Aeglea develops engineered human enzymes for rare metabolic diseases, providing a directly comparable enzymatic-therapy approach overlapping with Reneo's orphan metabolic focus.
- Crinetics Pharmaceuticals: Crinetics is a clinical-stage company developing therapies for rare endocrine diseases, sharing Reneo's small-molecule rare-disease development model and similar stage of maturity.
- Soleno Therapeutics: Soleno is a clinical-stage rare-disease company focused on metabolic and neurodevelopmental disorders, comparable to Reneo in scale, stage, and orphan-disease regulatory strategy.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Reneo Pharmaceuticals social profiles
Digital presenceReneo Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Reneo Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles7 records
Reneo Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds5 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Reneo Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Reneo Pharmaceuticals
What does Reneo Pharmaceuticals do?
Reneo Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule therapies for orphan metabolic diseases, including rare genetic mitochondrial and metabolic disorders. The company is pre-revenue and focused on discovering, developing, and advancing its proprietary pipeline of drug candidates through clinical trials targeting conditions of high unmet medical need.
Is Reneo Pharmaceuticals a public or private company?
Reneo Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was Reneo Pharmaceuticals founded?
Reneo Pharmaceuticals was founded in 2014. It employs 51 to 100 people.
Where is Reneo Pharmaceuticals based?
Reneo Pharmaceuticals is headquartered in San Diego, United States, in the North America region.
Who are Reneo Pharmaceuticals's main competitors?
Direct peers on record are BioMarin Pharmaceutical, Travere Therapeutics, Ultragenyx Pharmaceutical, Amicus Therapeutics and BridgeBio Pharma. Broad incumbents are Horizon Therapeutics (Amgen) and Alexion (AstraZeneca Rare Disease). Emerging players are Aeglea BioTherapeutics, Crinetics Pharmaceuticals and Soleno Therapeutics.
Does Reneo Pharmaceuticals have an API?
No public API is recorded for Reneo Pharmaceuticals.
What industry is Reneo Pharmaceuticals in?
Reneo Pharmaceuticals's product category is Rare Disease Pharmaceuticals. Its primary akta.pro industry code is HLAIAIAB, Enzyme Replacement & Metabolic Disorder Therapies, with a secondary code of HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2834.